抗白介素-1治疗成人斯蒂尔病有效且耐受良好的综合文献综述
该文献综述汇总了所有关于商业可及抗IL-1药物(阿那白滞素、卡那单抗、利纳西普)治疗难治性成人斯蒂尔病(AOSD)的报道。数据显示各药物完全或部分缓解率相似(91-100%),优于传统疗法,且具有显著激素节约效应,但关节受累反应较差。
要点
- 抗IL-1药物治疗AOSD的完全或部分缓解率达91-100%,优于传统疗法。
- 抗IL-1药物具有显著激素节约效应,并可减少或停用改善病情抗风湿药。
- 关节受累对治疗的反应似乎不如全身性特征,部分病例疗效随时间丧失。
核心结论
- 抗IL-1药物治疗AOSD有效,提示IL-1在AOSD发病机制中起核心作用。
研究设计与样本
- 综合文献综述,纳入所有关于商业可及抗IL-1药物(阿那白滞素、卡那单抗、利纳西普)治疗AOSD的疗效报道,排除未确诊或不典型AOSD及仅治疗罕见并发症的病例。
主要发现
- 各抗IL-1药物的完全或部分缓解率相似(91-100%),优于已发表的经典疗法结果。
- 原发性治疗失败罕见,但部分病例疗效随时间丧失,半衰期较长的较新抗IL-1药物可能显示更持久疗效。
- 关节受累对治疗的反应似乎不如疾病全身性特征。
- 长期随访显示疗效可能持续多年,抗IL-1药物具有显著激素节约效应,并可减少或停用改善病情抗风湿药。
关键数值与推荐
- 各抗IL-1药物治疗的完全或部分缓解率均为91-100%。
临床怎么用
- 对于难治性AOSD,及时使用抗IL-1药物可减缓疾病进展并减少治疗副作用。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The literature contains many reports of the use of commercially available anti-IL-1 agents (anakinra/Kineret®, canakinumab/Ilaris®, or rilonacept/Arcalyst®) in treatment-resistant adult-onset Still's disease (AOSD). These have been widely summarized in many review articles, but a full account of all reports with each of the agents used is not available. This literature review includes all reports of treatment outcomes in patients treated for AOSD with any commercially available anti-IL-1 agent (excluding cases of unconfirmed or atypical AOSD or treatments only for rare AOSD complications). The summary makes use of tabular formats, to identify the available reports and to provide data for compiling and comparison to classical therapies. For each anti-IL-1 agent used, a table shows the frequency of remission during treatment and the frequency of stopping or reducing steroid use, which were reported in almost all articles. A brief textual summary is used to describe other relevant but less often described efficacy aspects and any safety information. The compiled data show that treatment with all anti-IL-1 agents is effective in AOSD, indicating that IL-1 has a central role in the pathogenesis of AOSD. Rates of full or partial remission with each agent were similar to each other (91-100%) and superior to the outcomes published for classical therapies. Primary treatment failures were rare, but efficacy was lost over time in some cases. Of note, the newer anti-IL-1 agents with longer half-lives may show prolonged efficacy. An articular involvement seems to be less responsive than systemic features of disease. However, long-term follow-up shows that efficacy may persist for many years. There is substantial evidence that anti-IL-1 agents have a strong steroid-sparing effect and considerable evidence that the use of disease-modifying anti-rheumatic drugs can also be reduced or stopped. Thus, the use of anti-IL-1 agents may reduce the side-effects of co-treatment. The high response rate to anti-IL-1 agents, especially in refractory AOSD cases, suggests that their appropriate use in a timely manner can slow disease progression and reduce treatment side-effects.
引用
- Junge G, Mason J, Feist E, et al. Adult onset Still's disease-The evidence that anti-interleukin-1 treatment is effective and well-tolerated (a comprehensive literature review). Semin Arthritis Rheum. 2017. PMID: 28757235. doi:10.1016/j.semarthrit.2017.06.006
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。